Patents by Inventor Toshiro Sakai

Toshiro Sakai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formulations of enzalutamide
    Patent number: 11839689
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Grant
    Filed: November 11, 2022
    Date of Patent: December 12, 2023
    Assignees: Astellas Pharma Inc., Medivation Prostate Therapeutics LLC
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • Formulations of Enzalutamide
    Publication number: 20230210778
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: November 11, 2022
    Publication date: July 6, 2023
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20230122911
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: November 11, 2022
    Publication date: April 20, 2023
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • CONNECTION TERMINAL
    Publication number: 20230042851
    Abstract: A connection terminal having a copper alloy as a base material, the copper alloy comprising Zn in an amount of 21 mass % or more and 27 mass % or less, Sn in an amount of 0.6 mass % or more and 0.9 mass % or less, Ni in an amount of 2.5 mass % or more and 3.7 mass % or less, and P in an amount of 0.01 mass % or more and 0.03 mass % or less, and the balance being Cu and inevitable impurities, wherein the copper alloy has: a 0.2% proof stress of 620 MPa or higher and 700 MPa or lower, and an electrical conductivity of 15% IACS or higher and 20% IACS or lower.
    Type: Application
    Filed: January 12, 2021
    Publication date: February 9, 2023
    Applicants: AUTONETWORKS TECHNOLOGIES, LTD., SUMITOMO WIRING SYSTEMS, LTD., SUMITOMO ELECTRIC INDUSTRIES, LTD., MITSUBISHI MATERIALS CORPORATION
    Inventors: Toshiro SAKAI, Kingo FURUKAWA, Takeshi MASUDA, Tetsuya KUWABARA, Michio TAKASAKI
  • PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
    Publication number: 20210346392
    Abstract: In a pharmaceutical composition for oral administration comprising 6-(4,4-dimethylcyclohexyl)-4-[(1,1-dioxo-1?6-thiomorpholin-4-yl)methyl]-2-methylthieno[2,3-d]pyrimidine or a pharmaceutically acceptable salt thereof, a stable pharmaceutical composition for oral administration with rapid drug dissolution properties is provided. The pharmaceutical composition for oral administration contains a water-swellable substance, which is a polymer compound obtained by condensation polymerization of ?-glucose, a polymer compound obtained by condensation polymerization of ?-glucose, or a polymer compound having a pyrrolidone functional group.
    Type: Application
    Filed: August 30, 2019
    Publication date: November 11, 2021
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Ryo KOJIMA, Toshiro SAKAI, Ryota AZUMA, Marina TANAKA
  • TERMINAL FITTING
    Publication number: 20200321719
    Abstract: Provided is a terminal fitting comprising a substrate of an aluminum alloy having excellent strength and workability. A terminal fitting 10 comprises a substrate of an aluminum alloy containing 4.0 to 6.0 mass % of Mg and having 0.2% yield strength at 290 to 330 MPa. Preferably the breaking elongation of the aluminum alloy is 10% or greater and the average crystal particle diameter of the aluminum alloy is 10 ?m or smaller. Preferably the aluminum alloy further contains 0.4 to 1.8 mass % of Mn.
    Type: Application
    Filed: December 6, 2018
    Publication date: October 8, 2020
    Inventors: Toshiro SAKAI, Shigeru OGIHARA
  • Pharmaceutical Composition for Oral Administration Comprising Enzalutamide
    Publication number: 20200146977
    Abstract: Provided is a pharmaceutical composition for oral administration in which the solubility and/or dissolution properties of enzalutamide are improved and supersaturation is maintained. Also provided is a pharmaceutical composition for oral administration in which the oral absorbability of enzalutamide is improved. The pharmaceutical composition for oral administration comprises enzalutamide and polyvinyl alcohol.
    Type: Application
    Filed: April 27, 2018
    Publication date: May 14, 2020
    Inventors: Yoshiaki Umemoto, Takatsune Yoshida, Sachie Namiki, Akira Takagi, Ryo Kojima, Toshiro Sakai, Shinsuke Oba, Hajime Aoki
  • Pharmaceutical composition for oral administration
    Patent number: 10583087
    Abstract: Disclosed is a pharmaceutical composition for oral administration, comprising 1-{5-[(5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-4-[4-methoxy-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)carbamoyl]pyrazin-2-yl}pyperidine-4-carboxylic acid, which is a compound having pH-dependent solubility, or a pharmaceutically acceptable salt thereof, and a cellulose derivative. In the pharmaceutical composition for oral administration, the solubility and absorbability of the drug are improved.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: March 10, 2020
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Yumiko Suda, Toshiro Sakai, Ryo Kojima, Dal Oyama, Koji Nishimura, Kumi Naiki
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20200060976
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: April 1, 2019
    Publication date: February 27, 2020
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • Pharmaceutical composition for oral administration
    Patent number: 10548845
    Abstract: Disclosed is a pharmaceutical composition for oral administration, comprising 1-{5-[(5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-4-[4-methoxy-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)carbamoyl]pyrazin-2-yl}pyperidine-4-carboxylic acid, which is a compound having pH-dependent solubility, or a pharmaceutically acceptable salt thereof, and a cellulose derivative. In the pharmaceutical composition for oral administration, the solubility and absorbability of the drug are improved.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: February 4, 2020
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Yumiko Suda, Toshiro Sakai, Ryo Kojima, Dal Oyama, Koji Nishimura, Kumi Naiki
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20190209476
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: July 24, 2018
    Publication date: July 11, 2019
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • Pharmaceutical composition containing mirabegron
    Patent number: 10058536
    Abstract: To provide: (1) a modified release liquid (suspension) containing mirabegron, (2) a ready-to-suspend pharmaceutical composition containing mirabegron, and (3) a mirabegron-containing pharmaceutical composition that does not generate undissolved lumps, even when it is suspended at the time of use. The present invention relates to a pharmaceutical composition containing a complex of mirabegron or a pharmaceutically acceptable salt thereof with sodium polystyrene sulfonate.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: August 28, 2018
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Seiji Takae, Toshiro Sakai, Yuki Kasashima, Yurina Ansei, Tsuyoshi Kiyota
  • PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
    Publication number: 20180116965
    Abstract: Disclosed is a pharmaceutical composition for oral administration, comprising 1-{5-[(5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-4-[4-methoxy-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)carbamoyl]pyrazin-2-yl}pyperidine-4-carboxylic acid, which is a compound having pH-dependent solubility, or a pharmaceutically acceptable salt thereof, and a cellulose derivative. In the pharmaceutical composition for oral administration, the solubility and absorbability of the drug are improved.
    Type: Application
    Filed: April 27, 2016
    Publication date: May 3, 2018
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Yumiko SUDA, Toshiro SAKAI, Ryo KOJIMA, Dal OYAMA, Koji NISHIMURA, Kumi NAIKI
  • PHARMACEUTICAL COMPOSITION CONTAINING MIRABEGRON
    Publication number: 20180036288
    Abstract: To provide: (1) a modified release liquid (suspension) containing mirabegron, (2) a ready-to-suspend pharmaceutical composition containing mirabegron, and (3) a mirabegron-containing pharmaceutical composition that does not generate undissolved lumps, even when it is suspended at the time of use. The present invention relates to a pharmaceutical composition containing a complex of mirabegron or a pharmaceutically acceptable salt thereof with sodium polystyrene sulfonate.
    Type: Application
    Filed: March 31, 2016
    Publication date: February 8, 2018
    Applicant: ASTELLAS PHARMA INC.
    Inventors: SEIJI TAKAE, TOSHIRO SAKAI, YUKI KASASHIMA, YURINA ANSEI, TSUYOSHI KIYOTA
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20170224624
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: September 16, 2016
    Publication date: August 10, 2017
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20170027910
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: February 8, 2016
    Publication date: February 2, 2017
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • Keyboard musical instrument
    Patent number: 9520107
    Abstract: Provided is a keyboard musical instrument such as an acoustic piano or an electronic piano having an appearance and design similar to an acoustic piano, in which a fall board is made of a resin plate-shaped body, and hollow portions are provided inside the plate-shaped body. In addition, the plate-shaped body includes a plate-shaped resin foamed plate portion, and the hollow portions are made of plural air bubbles contained inside the resin foamed plate portion.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: December 13, 2016
    Assignee: Yamaha Corporation
    Inventors: Tadaharu Kato, Toshiro Sakai
  • KEYBOARD MUSICAL INSTRUMENT
    Publication number: 20150068382
    Abstract: Provided is a keyboard musical instrument such as an acoustic piano or an electronic piano having an appearance and design similar to an acoustic piano, in which a fall board is made of a resin plate-shaped body, and hollow portions are provided inside the plate-shaped body. In addition, the plate-shaped body includes a plate-shaped resin foamed plate portion, and the hollow portions are made of plural air bubbles contained inside the resin foamed plate portion.
    Type: Application
    Filed: September 8, 2014
    Publication date: March 12, 2015
    Inventors: TADAHARU KATO, Toshiro Sakai
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20140378517
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: September 10, 2014
    Publication date: December 25, 2014
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20140179749
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: September 11, 2013
    Publication date: June 26, 2014
    Applicants: BEND RESEARCH, ASTELLAS PHARMA INC., MEDIVATION PROSTATE THERAPEUTICS, INC.
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi